
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2546782/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	X-Linked Lymphoproliferative Disease. Journal of Experimental Medicine, 2000, 192, 337-346.	8.5	438
2	CD56brightCD16â^' Killer Ig-Like Receptorâ^' NK Cells Display Longer Telomeres and Acquire Features of CD56dim NK Cells upon Activation. Journal of Immunology, 2007, 178, 4947-4955.	0.8	430
3	HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 12000-12004.	7.1	419
4	CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: Induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10116-10121.	7.1	412
5	HLA-haploidentical stem cell transplantation after removal of αβ+ T and B cells in children with nonmalignant disorders. Blood, 2014, 124, 822-826.	1.4	385
6	Analysis of the receptor-ligand interactions in the natural killer–mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood, 2005, 105, 2066-2073.	1.4	344
7	Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood, 2009, 113, 3119-3129.	1.4	343
8	The natural killer cell receptor specific for HLA-A allotypes: a novel member of the p58/p70 family of inhibitory receptors that is characterized by three immunoglobulin-like domains and is expressed as a 140-kD disulphide-linked dimer Journal of Experimental Medicine, 1996, 184, 505-518.	8.5	340
9	The human leukocyte antigen (HLA)-C-specific "activatory" or "inhibitory" natural killer cell receptors display highly homologous extracellular domains but differ in their transmembrane and intracytoplasmic portions Journal of Experimental Medicine, 1996, 183, 645-650.	8.5	326
10	The Therapeutic Targets of miRNA in Hepatic Cancer Stem Cells. Stem Cells International, 2016, 2016, 1-10.	2.5	320
11	Mitochondria as playmakers of apoptosis, autophagy and senescence. Seminars in Cell and Developmental Biology, 2020, 98, 139-153.	5.0	305
12	Gntb-A, a Novel Sh2d1a-Associated Surface Molecule Contributing to the Inability of Natural Killer Cells to Kill Epstein-Barr Virus–Infected B Cells in X-Linked Lymphoproliferative Disease. Journal of Experimental Medicine, 2001, 194, 235-246.	8.5	287
13	Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation. Frontiers in Immunology, 2019, 10, 1179.	4.8	269
14	Outcome of children with acute leukemia given HLA-haploidentical HSCT after αβ T-cell and B-cell depletion. Blood, 2017, 130, 677-685.	1.4	261
15	Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: a role for human cytomegalovirus?. Blood, 2012, 119, 399-410.	1.4	241
16	Generation of allospecific natural killer cells by stimulation across a polymorphism of HLA-C. Science, 1993, 260, 1121-1124.	12.6	223
17	Amino acid substitutions can influence the natural killer (NK)-mediated recognition of HLA-C molecules. Role of serine-77 and lysine-80 in the target cell protection from lysis mediated by "group 2" or "group 1" NK clones Journal of Experimental Medicine, 1995, 182, 605-609.	8.5	209
18	2B4 functions as a co-receptor in human NK cell activation. European Journal of Immunology, 2000, 30, 787-793.	2.9	202

#	Article	IF	CITATIONS
19	Identification and Molecular Cloning of P75/Airm1, a Novel Member of the Sialoadhesin Family That Functions as an Inhibitory Receptor in Human Natural Killer Cells. Journal of Experimental Medicine, 1999, 190, 793-802.	8.5	201
20	Identification of NKp80, a novel triggering molecule expressed by human NK cells. European Journal of Immunology, 2001, 31, 233-242.	2.9	185
21	Human Cytomegalovirus Infection Promotes Rapid Maturation of NK Cells Expressing Activating Killer Ig–like Receptor in Patients Transplanted with NKG2Câ^'/â^' Umbilical Cord Blood. Journal of Immunology, 2014, 192, 1471-1479.	0.8	176
22	HLA-E-restricted recognition of cytomegalovirus-derived peptides by human CD8+ cytolytic T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 10896-10901.	7.1	175
23	Early expression of triggering receptors and regulatory role of 2B4 in human natural killer cell precursors undergoing in vitro differentiation. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 4526-4531.	7.1	174
24	p49, a putative HLA class I-specific inhibitory NK receptor belonging to the immunoglobulin superfamily. European Journal of Immunology, 1998, 28, 1980-1990.	2.9	144
25	Engagement of p75/AIRM1 or CD33 inhibits the proliferation of normal or leukemic myeloid cells. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 15091-15096.	7.1	137
26	A novel surface molecule homologous to the p58/p50 family of receptors is selectively expressed on a subset of human natural killer cells and induces both triggering of cell functions and proliferation. European Journal of Immunology, 1996, 26, 1816-1824.	2.9	126
27	NK Cells Mediate a Crucial Graft-versus-Leukemia Effect in Haploidentical-HSCT to Cure High-Risk Acute Leukemia. Trends in Immunology, 2018, 39, 577-590.	6.8	119
28	Differences in HLA class II alleles of isolated South American Indian populations from Brazil and Argentina. Human Immunology, 1993, 37, 213-220.	2.4	117
29	Analysis of natural killer cells isolated from human decidua: evidence that 2B4 (CD244) functions as an inhibitory receptor and blocks NK-cell function. Blood, 2006, 108, 4078-4085.	1.4	117
30	Human NK cells directly recognize Mycobacterium bovis via TLR2 and acquire the ability to kill monocyte-derived DC. International Immunology, 2008, 20, 1155-1167.	4.0	110
31	Structural basis for a major histocompatibility complex class Ib–restricted T cell response. Nature Immunology, 2006, 7, 256-264.	14.5	109
32	Expression and function of KIR and natural cytotoxicity receptors in NK-type lymphoproliferative diseases of granular lymphocytes. Blood, 2003, 102, 1797-1805.	1.4	106
33	Natural killer cells expressing the KIR2DS1-activating receptor efficiently kill T-cell blasts and dendritic cells: implications in haploidentical HSCT. Blood, 2011, 117, 4284-4292.	1.4	104
34	Human Natural Killer cell receptors: insights into their molecular function and structure. Journal of Cellular and Molecular Medicine, 2003, 7, 376-387.	3.6	102
35	Cellular and molecular basis of haploidentical hematopoietic stem cell transplantation in the successful treatment of high-risk leukemias: role of alloreactive NK cells. Frontiers in Immunology, 2013, 4, 15.	4.8	98
36	The analysis of the natural killer-like activity of human cytolytic T lymphocytes revealed HLA-E as a novel target for TCR α/β-mediated recognition. European Journal of Immunology, 2001, 31, 3687-3693.	2.9	91

#	Article	IF	CITATIONS
37	Anticancer and Anti-Inflammatory Properties of Ganoderma lucidum Extract Effects on Melanoma and Triple-Negative Breast Cancer Treatment. Nutrients, 2017, 9, 210.	4.1	91
38	Homophilic interaction of NTBA, a member of the CD2 molecular family: induction of cytotoxicity and cytokine release in human NK cells. European Journal of Immunology, 2004, 34, 1663-1672.	2.9	90
39	Identification of HLA-E-specific alloreactive T lymphocytes: A cell subset that undergoes preferential expansion in mixed lymphocyte culture and displays a broad cytolytic activity against allogeneic cells. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11328-11333.	7.1	87
40	HLA-G recognition by human natural killer cells. Involvement of CD94 both as inhibitory and as activating receptor complex. European Journal of Immunology, 1997, 27, 1875-1880.	2.9	84
41	A novel KIR-associated function: evidence that CpG DNA uptake and shuttling to early endosomes is mediated by KIR3DL2. Blood, 2010, 116, 1637-1647.	1.4	83
42	DNA typing for HLA class I alleles: I. Subsets of HLA-A2 and of -A28. Human Immunology, 1992, 33, 163-173.	2.4	81
43	Killer cell immunoglobulin-like receptor 3DL1 polymorphism defines distinct hierarchies of HLA class I recognition. Journal of Experimental Medicine, 2016, 213, 791-807.	8.5	81
44	Analysis of memory-like natural killer cells in human cytomegalovirus-infected children undergoing ÂÂ+T and B cell-depleted hematopoietic stem cell transplantation for hematological malignancies. Haematologica, 2016, 101, 371-381.	3.5	80
45	CD59 is physically and functionally associated with natural cytotoxicity receptors and activates human NK cell-mediated cytotoxicity. European Journal of Immunology, 2003, 33, 3367-3376.	2.9	77
46	Human NK Cells: From Surface Receptors to the Therapy of Leukemias and Solid Tumors. Frontiers in Immunology, 2014, 5, 87.	4.8	77
47	Identification of effector-memory CMV-specific T lymphocytes that kill CMV-infected target cells in an HLA-E-restricted fashion. European Journal of Immunology, 2005, 35, 3240-3247.	2.9	76
48	Rock-type control on erosion-induced uplift, eastern Swiss Alps. Earth and Planetary Science Letters, 2009, 278, 278-285.	4.4	66
49	<scp>KIR</scp> and <scp>KIR</scp> ligand polymorphism: a new area for clinical applications?. Tissue Antigens, 2013, 82, 363-373.	1.0	60
50	Molecular features of the hepatitis B virus nucleocapsid T-cell epitope 18-27: Interaction with HLA and T-cell receptor. Hepatology, 1997, 26, 1027-1034.	7.3	57
51	An Historical Overview: The Discovery of How NK Cells Can Kill Enemies, Recruit Defense Troops, and More. Frontiers in Immunology, 2019, 10, 1415.	4.8	57
52	NK Cell-Based Immunotherapy for Hematological Malignancies. Journal of Clinical Medicine, 2019, 8, 1702.	2.4	54
53	Evidence that the KIR2DS5 gene codes for a surface receptor triggering natural killer cell function. European Journal of Immunology, 2008, 38, 2284-2289.	2.9	53
54	ERAP1 Regulates Natural Killer Cell Function by Controlling the Engagement of Inhibitory Receptors. Cancer Research, 2015, 75, 824-834.	0.9	52

#	Article	IF	CITATIONS
55	p75/AIRM1 and CD33, two sialoadhesin receptors that regulate the proliferation or the survival of normal and leukemic myeloid cells. Immunological Reviews, 2001, 181, 260-268.	6.0	47
56	ldentification of the rat homologue of the human NKp46 triggering receptor. Immunology Letters, 1999, 68, 411-414.	2.5	44
57	Mouse Models in Prostate Cancer Translational Research: From Xenograft to PDX. BioMed Research International, 2016, 2016, 1-11.	1.9	43
58	HLA-E–restricted recognition of human cytomegalovirus by a subset of cytolytic T lymphocytes. Human Immunology, 2004, 65, 437-445.	2.4	42
59	Late Development of FcεRγneg Adaptive Natural Killer Cells Upon Human Cytomegalovirus Reactivation in Umbilical Cord Blood Transplantation Recipients. Frontiers in Immunology, 2018, 9, 1050.	4.8	42
60	Impact of HCMV Infection on NK Cell Development and Function after HSCT. Frontiers in Immunology, 2013, 4, 458.	4.8	41
61	Suspension feeding in adult Nephrops norvegicus (L.) and Homarus gammarus (L.) (decapoda). Journal of Sea Research, 1993, 31, 291-297.	1.0	39
62	Human natural killer cell activating receptors. Molecular Immunology, 2000, 37, 1015-1024.	2.2	36
63	Human NK receptors: From the molecules to the therapy of high risk leukemias. FEBS Letters, 2011, 585, 1563-1567.	2.8	36
64	Susceptibility of Human Melanoma Cells to Autologous Natural Killer (NK) Cell Killing: HLA-Related Effector Mechanisms and Role of Unlicensed NK Cells. PLoS ONE, 2009, 4, e8132.	2.5	36
65	Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias. Cancer Immunology, Immunotherapy, 2016, 65, 465-476.	4.2	34
66	GPR56 as a novel marker identifying the CD56dull CD16+ NK cell subset both in blood stream and in inflamed peripheral tissues. International Immunology, 2010, 22, 91-100.	4.0	33
67	Combined Genotypic and Phenotypic Killer Cell Ig-Like Receptor Analyses Reveal KIR2DL3 Alleles Displaying Unexpected Monoclonal Antibody Reactivity: Identification of the Amino Acid Residues Critical for Staining. Journal of Immunology, 2010, 185, 433-441.	0.8	32
68	Role of Nigella sativa and Its Constituent Thymoquinone on Chemotherapy-Induced Nephrotoxicity: Evidences from Experimental Animal Studies. Nutrients, 2017, 9, 625.	4.1	32
69	Analysis of HLA DP, DQ, and DR allesles in adult Italian rheumatoid arthritis patients. Human Immunology, 1992, 34, 135-141.	2.4	28
70	Distinctive Lack of CD48 Expression in Subsets of Human Dendritic Cells Tunes NK Cell Activation. Journal of Immunology, 2005, 175, 3690-3697.	0.8	26
71	Heterogeneity of TLR3 mRNA transcripts and responsiveness to poly (I:C) in human NK cells derived from different donors. International Immunology, 2007, 19, 1341-1348.	4.0	26
72	Extending killer Ig-like receptor function: from HLA class I recognition to sensors of microbial products. Trends in Immunology, 2010, 31, 289-294.	6.8	24

#	Article	IF	CITATIONS
73	KIR3DS1-Mediated Recognition of HLA-*B51: Modulation of KIR3DS1 Responsiveness by Self HLA-B Allotypes and Effect on NK Cell Licensing. Frontiers in Immunology, 2017, 8, 581.	4.8	24
74	The Role of miRNAs in the Regulation of Pancreatic Cancer Stem Cells. Stem Cells International, 2016, 2016, 1-7.	2.5	23
75	p49, A putative HLA-G1-specific inhibitory NK receptor belonging to the Immunoglobulin Superfamily. Journal of Reproductive Immunology, 1999, 43, 157-165.	1.9	22
76	TCRαβ/CD19 depleted HSCT from an HLA-haploidentical relative to treat children with different nonmalignant disorders. Blood Advances, 2022, 6, 281-292.	5.2	22
77	Hematopoietic stem cell transplantation: Improving alloreactive Bw4 donor selection by genotyping codon 86 of KIR3DL1/S1. European Journal of Immunology, 2016, 46, 1511-1517.	2.9	21
78	Tumour biomarkers: homeostasis as a novel prognostic indicator. Open Biology, 2016, 6, 160254.	3.6	21
79	<scp>XLP</scp> 1 inhibitory effect by 2 <scp>B</scp> 4 does not affect <scp>DNAM</scp> â€1 and <scp>NKG</scp> 2 <scp>D</scp> activating pathways in <scp>NK</scp> cells. European Journal of Immunology, 2014, 44, 1526-1534.	2.9	20
80	A conserved energetic footprint underpins recognition of human leukocyte antigen-E by two distinct αβ T cell receptors. Journal of Biological Chemistry, 2017, 292, 21149-21158.	3.4	20
81	A novel HLA-DRB1 allele (DRB1*0417) in South American Indians. Immunogenetics, 1993, 38, 463-463.	2.4	19
82	DQA1â^—03 subtypes have different associations with DRB1 and DQB1 alleles. Human Immunology, 1994, 39, 290-298.	2.4	19
83	Phenotypic and Functional Characterization of NK Cells in $\hat{1}\pm\hat{1}^2$ T-Cell and B-Cell Depleted Haplo-HSCT to Cure Pediatric Patients with Acute Leukemia. Cancers, 2020, 12, 2187.	3.7	19
84	Electrochemotherapy in pancreatic adenocarcinoma treatment: pre-clinical and clinical studies. Radiology and Oncology, 2016, 50, 14-20.	1.7	19
85	Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia. Cancer Immunology Research, 2022, 10, 291-302.	3.4	17
86	Production of two human hybridomas secreting antibodies to HLA-DRw11 and -DRw8+w12 specificities. Human Immunology, 1991, 31, 86-93.	2.4	16
87	Identification and molecular characterization of a natural mutant of the p50.2/KIR2DS2 activating NK receptor that fails to mediate NK cell triggering. European Journal of Immunology, 2000, 30, 3569-3574.	2.9	15
88	Isolation of a novel KIR2DL3-specific mAb: comparative analysis of the surface distribution and function of KIR2DL2, KIR2DL3 and KIR2DS2. International Immunology, 2004, 16, 1459-1466.	4.0	15
89	Inhibitory 2B4 contributes to NK cell education and immunological derangements in XLP1 patients. European Journal of Immunology, 2017, 47, 1051-1061.	2.9	15
90	Identification of NKp80, a novel triggering molecule expressed by human NK cells. European Journal of Immunology, 2001, 31, 233-242.	2.9	15

#	Article	IF	CITATIONS
91	Diagnosing XLP1 in patients with hemophagocytic lymphohistiocytosis. Journal of Allergy and Clinical Immunology, 2014, 134, 1381-1387.e7.	2.9	14
92	Natural killer cells: From surface receptors to the cure of highâ€risk leukemia (Ceppellini Lecture). Hla, 2019, 93, 185-194.	0.6	11
93	Characterization of two human monoclonal antibodies recognizing HLAâ€A30 and HLAâ€A3+A31, respectively. Tissue Antigens, 1991, 38, 224-227.	1.0	10
94	Haploidentical Stem Cell Transplantation After TCR-αβ+ and CD19+ Cells Depletion In Children With Congenital Non-Malignant Disease. Transplantation and Cellular Therapy, 2022, 28, 394.e1-394.e9.	1.2	10
95	CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma. Frontiers in Immunology, 2022, 13, 837457.	4.8	9
96	HLA-DPB1 alleles in a population from South China. Immunogenetics, 1993, 37, 251-6.	2.4	8
97	Analysis of <i>KIR3DP1</i> Polymorphism Provides Relevant Information on Centromeric <i>KIR</i> Gene Content. Journal of Immunology, 2018, 201, 1460-1467.	0.8	7
98	ERAP1 Controls the Interaction of the Inhibitory Receptor KIR3DL1 With HLA-B51:01 by Affecting Natural Killer Cell Function. Frontiers in Immunology, 2021, 12, 778103.	4.8	6
99	Impact of Donor-Specific anti-HLA antibodies and donor KIR characteristics in haploidentical HSCT for beta-Thalassemia. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 9, e2017020.	1.3	5
100	Cytokine-Induced Memory-Like NK Cells with High Reactivity against Acute Leukemia Blasts and Solid Tumor Cells Suitable for Adoptive Immunotherapy Approaches. Cancers, 2021, 13, 1577.	3.7	5
101	Characterization of <scp>KIR</scp> ⁺ <scp>NK</scp> cell subsets with a monoclonal antibody selectively recognizing <scp>KIR2DL1</scp> and blocking the specific interaction with <scp>HLA </scp> . Hla, 2022, , .	0.6	5
102	Molecular Structures of HLA-Specific Human NK Cell Receptors. Chemical Immunology and Allergy, 1996, 64, 88-103.	1.7	4
103	Regulation of myeloid cell proliferation and survival by p75/AIRM1 and CD33 surface receptors. Advances in Experimental Medicine and Biology, 2001, 495, 55-61.	1.6	4
104	Removal Of Alpha/Beta+ T Cells and Of CD19+ B Cells From The Graft Translates Into Rapid Engraftment, Absence Of Visceral Graft-Versus-Host Disease and Low Transplant-Related Mortality In Children With Acute Leukemia Given HLA-Haploidentical Hematopoietic Stem Cell Transplantation. Blood, 2013, 122, 157-157.	1.4	4
105	Production and characterization of murine monoclonal antibodies recognizing HLA-DQ polymorphisms obtained by immunizing mice with transfected L cells. Human Immunology, 1992, 34, 126-134.	2.4	3
106	Normal Epithelial Cells Modulating HLA Class I Surface Molecules Are Susceptible to Lysis Mediated by CD3+and CD3â^'"Nonspecific―Killer Cells. Cellular Immunology, 1998, 190, 183-190.	3.0	3
107	X-linked lymphoproliferative disease: the dark side of 2b4 function. Advances in Experimental Medicine and Biology, 2001, 495, 63-67.	1.6	3
108	Epitope characterization of a monoclonal antibody that selectively recognizes <scp>KIR2DL1</scp> allotypes. Hla, 2022, , .	0.6	3

MICHELA FALCO

#	Article	IF	CITATIONS
109	Molecular Structures of HLA-Specific Human NK Cell Receptors. Chemical Immunology and Allergy, 1996, 64, 88-103.	1.7	2
110	Anti-Leukemia Activity of Alloreactive NK Cells in Haploidentical HSCT in Pediatric Patients: Re-Defining the Role of Activating and Inhibitory KIR. Blood, 2008, 112, 3002-3002.	1.4	2
111	Alpha/Beta T-Cell and B-Cell Depletion HLA-Haploidentical Hematopoietic Stem Cell Transplantation Is an Effective Treatment for Children/Young Adults with Acute Leukemia. Blood, 2018, 132, 2169-2169.	1.4	1
112	Natural Killer (NK) Alloreactivity Seems Not to Play a Role in Preventing Leukemia Relapse in Unmanipulated Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide. Blood, 2015, 126, 2033-2033.	1.4	1
113	T-Cell Depleted HLA-Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (haplo-HSCT) Followed By Donor Lymphocyte Infusion with T Cells Transduced with the Inducible Caspase 9 (iC9) Suicide Gene in Children with Hematological Malignancies. Blood, 2016, 128, 4683-4683.	1.4	1
114	ANALYSIS OF HLA SPECIFICITY OF HUMAN MONOCLONAL ANTIBODIES BY CYTOFLUORIMETRY AND CELL ELISA. International Journal of Immunogenetics, 1991, 18, 345-353.	1.2	0
115	Allelic distribution of DQA1, DQB1, DRB1 and DPB1 in 13 populations suggest a distinctive evolutionary history for the DPB1 locus. Human Immunology, 1993, 37, 26.	2.4	0
116	Allospecific natural killer cells are generated by reciprocal stimulation across a diallelic polymorphism of HLA-C. Human Immunology, 1993, 36, 66.	2.4	0
117	Analysis of HLA-C polymorphism by PCR and SSO. Human Immunology, 1993, 36, 56.	2.4	0
118	HLA-C locus polymorphism analyzed by molecular approach. Human Immunology, 1993, 37, 18.	2.4	0
119	OR.69. Hla-E-Restricted Cytolytic T Lymphocytes: Their Role in Cytomegalovirus Infection and Transplantation. Clinical Immunology, 2006, 119, S29-S30.	3.2	0
120	OR.69. Alloreactive NK Cells Exert Anti-leukemia Activity in Haplo-HSCT to Pediatric Patients: Revised Role of Activating and Inhibitory KIR. Clinical Immunology, 2009, 131, S29.	3.2	0